and this The Good with the on study Tina Rezdiffra. the FXc we've for patients, data an Tina. of benefit promising Rezdiffra's high-risk XXXX. we're from morning, for U.S. mentioned. Today, also very on X-year with strong, the significant ended year patient population, in how approved. new are thanks, support Well, if to building share update and thanks update pleased potential as I'll an XXXX started results We provide we're joining. I'll and momentum an launch open-label
of to a the I lot medicines. and attest reflect a ahead, I've the in of a and want I'll on XXXX, time, to for amount foundation We a therapy. let look year moment exceed potentially to the industry for remarkable launch our transformation long take the meet to successful of first-in-disease a to be been no the first to achievement And successful we blockbuster before any is alone for launch, of Rezdiffra launched But I've company. Rezdiffra work to worked year started last therapy. high tremendous the lay required exception. become a or and expectations
would the highlighted aspirations. launch incredibly the that and on I'm we things accomplishments team world-class are said Madrigal's support them. Rezdiffra of These Slide built that we of our did drive proud X. to team's We we do, a long-term and
Rezdiffra of we On the approved first-ever Phase the MASH for III XX, disease. New the the field, in groundbreaking milestone trial March were treatment Our for Medicine. England Journal published approval data the landmark achieved of Rezdiffra, this
expanding Europe trial. was to validated their Rezdiffra's MAESTRO-NASH achievement therapy MASH. progress Europe reach, updating made we societies top-tier U.S., both and Rezdiffra And for liver as X our geographically This submitting in for first-line and in approval guidelines include by the completing clinically, both and enrollment outcomes in significant Rezdiffra further
Rezdiffra leader in and Importantly, the benefiting as these for of translating now strong are thousands accomplishments patients foundation future into from a Madrigal's NASH. building
update launch Let's on X. Slide move to the U.S. Rezdiffra
range. X- quarter-over-quarter reflecting JPMorgan this another to our well generated previewed quarter in we sales and January, morning within strong earnings demand growth. net with at million XXXX, in $XXX XX% first the of release quarter was This our As inventory in detailed fourth we expected X-week in
quarters sales, $XXX of million represent in launched April, we figures year we a the XXXX, remarkable X and these considering generated full in just For net performance. achievement
line community, in urgent with excellent the track in MASH trajectory successful launch Rezdiffra in product of confirms the need This the some the addressing medicine to most its exceptional past is of team. Our launches profile decade. specialty continues the our execution and
financial critical by on indicators to quarter the results drug our performance key access. quarter payer metrics. launch, XXXX, the patients driven great a for reached progress we've we X successful are launch strong any and In of the greater on ahead milestone Since of key to therapy, commercial These achieving schedule, third XX% metric, make on then, prescribers Rezdiffra. other coverage X than continued
patients. on First,
months. accomplishment As the milestone, continue noted rate with patients is the ended more XX,XXX consistent medicine steadily that's Rezdiffra, just significant to XX,XXX with Slide X other Crossing patient fourth quarter threshold launches. top-tier we add on at in incredible X, than a specialty on an a we patients and
represents this any actively sustained it meaningful treatment meaning Importantly, figure adoption. rigorous making therapy, the patients accounts on it for metric discontinuations, and track to most
Yet, we're still in the days. early
of the We XXX,XXX MASH. XXX,XXX FX We of a on with less patients Rezdiffra, attractive have a with penetrated which remain market. only diagnosed X% specialty the fraction the diagnosed than patients, FX, represents market focused highly
the multiples in years believe ahead. stated the strength of that to the XXX,XXX. expanding are the profile Rezdiffra's of creating scenario, the multiple paths efforts success leadership of for focused it either market We next on ahead, in positions entrant Looking Rezdiffra to for many
our for growth. patient ahead. to we expect patients talked Rezdiffra And we've foundation we've is in sustained ability X, build we're in penetration the support practice change increased as directly years the providers, driven the real seeing prescription From infrastructure been helped wiring to engaged we have progress of and about clinical the volume the necessary Our day base. laying system, steadily prescriber quarter-over-quarter to tied add how
X, the progress. the bar illustrates on this graph On left Slide
of with quarter. our prescribers. up from on quarter, the targets target our team approximately focused a XX% In primarily and XX,XXX X,XXX is fourth effort X,XXX reminder, field of a on total in the As concentrated gastroenterologists prescribed the top top prescribers, hepatologists XX% a third Rezdiffra,
exceptionally we successful other increased blockbuster are seeing metrics writers. and depth prescribers, well of are with current new launches. from adding steadily are prescribing We tracking Both
top As our expected, driven of more our than prescribers have XX% target prescriptions.
to Just expanding build of our potential. adoption sales foundation XX% prescriber peak towards shaping driven we had practice already year-end, of as access Rezdiffra strong its we prescribers, continue full clinical plan making across target prescribed as base We're XX,XXX the our growing By and meaningful approximately reflecting we've and successfully among progress. top support. Rezdiffra, a
for adherence is or of profile dosing. in being broad-based comparable and indicate halts its years. a uptake chronic patients fibrosis And a It's early a a pill XX% out liver liver liver-directed MASH, It's that to Rezdiffra's supports disease continuing to rates with other data driven liver attractive well-tolerated simple long-term well-tolerated profile. oral serious by improves like proxy once-daily stiffness, to X persistency therapy with this with favorable therapies. also
and real-world and hearing body. in medicine, really increased from Rezdiffra from tests me outcomes "living diagnosed overwhelmingly like liver Rezdiffra recently She feedback patient back." And Rezdiffra function We in and MASH. in including also the physical levels, and positive time said, both with reduced patients. heard of hope physicians gave X my with the to bomb fatigue, life improvements my We're activity FX They on continue benefits lipid matter. highlight these felt fibrosis. having a improvement MASH
and in patients the be for to to years many help come. MASH leader is goal Our
the of noted success Rezdiffra's U.S. As launch. Slide on builds strategy X, on our long-term
Rezdiffra Europe. track on expanding and are for in remain decision geographically midyear a we regulatory First, for
outcome, approach take beginning second Assuming of in we commercialization, a the to with a positive to the plan targeted half Germany year. country-by-country
attractive Europe, in opportunities patients to are additional also Beyond geographies. we assessing bring to Rezdiffra
field more we MASH moment. the cirrhosis. shared with compensated Second, expanding market Rezdiffra some I'll morning step we're in for opportunity. and and major doubling on the a represent Approval landscape this the patients MASH for data for treatment spend advancing effectively FXc significantly would time a patients, in Rezdiffra's forward
third, highly enviable MASH pipeline are building are building it. to And today, pipeline the the and focused meaningful the we to in providing We're a position community right Rezdiffra. we medicine a now on behind of committed beyond strong
mechanisms of at position evaluating strengthening with different action, and stages the extending goal MASH. all development in assets across leadership multiple of are our We of
the cancer Slide cirrhosis death. a substantial hypertension, variceal portal complications to progressive which loss from bleeding. portion XX leads and in also often damage, ascites patients unmet MASH cirrhosis. compensated need of to MASH disease liver compensated life-threatening and significant and liver suffer encephalopathy, A of liver Moving function, characterized by such chronic hepatic It's liver as
FX, patients at a are While FX with XXx higher staggering a risk fibrosis to risk. FX mortality, XXx face of increased patients XXx liver-related
informed our This the cirrhosis the trials in is is surrogate endpoint guidance, very adverse compensated opposed preventing ongoing that recommends use outcomes as as goal. FDA This guidance, outcomes clinical FXc our along MASH biopsy-based reflected open-label patient to of progression central which design cohort OUTCOMES endpoints. MAESTRO-NASH clinical sick In treatment this with trial. FX data from an population, to in
FX to Rezdiffra's and benefit but patients, that in Slide well. with as cirrhosis FXc compensated of FXc. deliver safety evaluating MAESTRO-NAFLD-X should Therefore, a not in mechanism arm liver-directed believe separate begin MASH included FX XX, We MASH open-label action on as a shown we treatment active of only efficacy patients MASH in patients Rezdiffra's our trial in
III safety to randomized, support reminder, a MAESTRO-NAFLD-X trial approval. regulatory a placebo-controlled As was double-blind, Phase
measures test is this used on transient previously as stiffness liver or presented a fibrosis. data FXc We a conducted new of for Slide outcomes. from X-year FibroScan trial VCTE X-year predictor data are XX. and elastography clinical cohort a of patients It's that in positive the with strong widely XXX highlighting VCTE proxy noninvasive vibration-controlled also a
at reduction The FXc reported or achieved kPa population in to results liver date. stiffness patient mean which years, in X-year largest X.X mean patients the kilopascal represents a an KPA show MASH that reduction X
a X Physicians reduction single-arm liver-related use baseline. events this patients with Baveno MASH. highly was the versus Rule stratify to in statistically was this of While trial, of significant KPa risk open-label
many into category. X.X% risk are reduction that a a So suggests patients lower moving
trials events. other associated or in profile of level low more reduction And measured meeting. look We XX% of stiffness liver by rate from with and VCTE. X-year forward details liver to Rezdiffra's its greater with of disease, complications. XX% achieved risks to this future safety patients away a Rezdiffra liver consistent a adverse end-stage of been at as cirrhosis progression was from This medical stiffness moving the due sharing has in to a patients discontinuations with further cohort reduced clinical decrease
of trial. high-risk in body this Rezdiffra's confidence the enrolled cirrhosis evidence population data to growing potential our These patient continued fully in benefit and supporting support add OUTCOMES
evaluating XX, on trial III Phase events Slide patients with MAESTRO-NASH compensated decompensation noted a double-blind, cirrhosis. OUTCOMES is large placebo-controlled progression to MASH liver As XXX in
data announce trial in this expect We XXXX. from to
the believe will and is FXc MAESTRO-NASH FX be today's Rezdiffra the regulatory obtains looking Rezdiffra So therapy and assuming we to FXc results and opportunity ahead leading OUTCOMES translate in to to in period. approval,
summarize briefly We Rezdiffra XXXX progress me for X% Before continued see an let growth profile, well and transformational than target We secured year approval highly on positioned U.S. in momentum FDA Slide a our on for runway XXXX XX. beyond. a I executing over penetrated are of the market Madrigal. hand launch. it to Rezdiffra Mardi, was and less successful significant for for is attractive with real-world strong and
for and We We believe global And build pipeline. be we significant will future are the we FXc expansion. in a our opportunity we opportunities market. to for preparing actively see explore expand continue to as to first
to turn With I'll that, it Mardi. over
